Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...

Another issue for investors is that Eli Lilly adjusted its guidance for the year, now projecting its adjusted EPS to fall ...

Concerns about Lilly's Q3 update are overblown. Lilly's impressive growth story remains intact. The stock's valuation is ...

Viking says an early-stage study of its obesity pill VK2735 showed adults on the highest dosage lost 8.2% of their body ...

When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 830% — a ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

Eli Lilly (LLY) Stock Price Prediction in 2025 The current Wall Street consensus 1-year price target of Eli Lilly stock is $1030.00, which is 28.35% higher than today’s price of $802.49.

Type 2 diabetes drug Mounjaro and weight-loss drug Zepbound remained the brightest stars in Lilly's lineup. Mounjaro's sales ...

Eli Lilly and Company disappointed with missed earnings, lower guidance. Click here for my review of LLY Q3 earnings and a ...

However, Eli Lily is a fast-growing company, with a price/earnings-to-growth ratio (PEG ratio) of only 0.5. PEGs under 1 are ...